Ciprofloxacin Inhale - A Pharmacokinetic(PK)/pharmacodynamic(PD) Rationale

被引：0
|
作者：
Stass, H. [1 ]
Dalhoff, A. [2 ]
机构：
[1] Bayer Schering Pharma, Wuppertal, Germany
[2] Univ Hosp SH, Kiel, Germany
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2010年 / 181卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1820
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The significance of distribution of pharmacokinetic (PK) and pharmacodynamic (PD) variabilities in determining clinical outcomes.
    Sun, HH
    Parekh, A
    Chatterjee, DJ
    Zhao, HH
    Pelsor, F
    Lazor, J
    Malinowski, H
    Hunt, J
    Lesko, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P75 - P75
  • [42] PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) BUMETANIDE (B) DOSE-RANGING STUDY IN INFANTS
    SULLIVAN, JE
    WITTE, MK
    YAMASHITA, TS
    BLUMER, JL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 179 - 179
  • [43] Pharmacodynamic and pharmacokinetic (PK/PD) pooled modelling of the antihypertensive response to amlodipine in hypertensive cats
    Pelligand, L.
    Bijsmans, E.
    Doig, M.
    Elliott, J.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2015, 38 : 26 - 27
  • [44] The science of erythropoicsis: Quantification of factors influencing response by pharmacokinetic (PK) and pharmacodynamic (PD) modeling
    Jumbe, NL
    Rossi, G
    Heatherington, AC
    Colowick, A
    BLOOD, 2002, 100 (11) : 9B - 9B
  • [45] How pharmacokinetic-pharmacodynamic (PK-PD) parameters influence antibiotic use
    Mazzei, T.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 : 19 - 21
  • [46] Are changes in the pharmacokinetic (PK) and pharmacodynamic (PD) properties of antipsychotics able to improve efficacy and safety?
    Luca Pani
    Annals of General Psychiatry, 7 (Suppl 1)
  • [47] Pharmacokinetic/pharmacodynamic (PK/PD) Characteristics of Veliparib with and without Temozolomide in Patients with Hematological Malignancies
    Singh, Renu
    Gopalakrishnan, Mathangi
    Kiesel, Brian F.
    Greer, Jacqueline M.
    Karp, Judith E.
    Gojo, Ivana
    Gobburu, Jogarao
    Rudek, Michelle A.
    Beumer, Jan H.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S31 - S32
  • [48] Pharmacokinetic-Pharmacodynamic (PK-PD) Model for Tolvaptan in Patients with Hypervolemic Hyponatremia
    Van Wart, Scott
    Shoaf, Susan
    Mallikaarjun, Suresh
    Mager, Donald
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S76 - S76
  • [49] Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
    Lei, Zhixin
    Liu, Qianying
    Xiong, Jincheng
    Yang, Bing
    Yang, Shuaike
    Zhu, Qianqian
    Li, Kun
    Zhang, Shishuo
    Cao, Jiyue
    He, Qigai
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [50] The pharmacokinetic and pharmacodynamic (PK/PD) interaction of ifetroban, a TXA(2) receptor antagonist, and heparin
    Liao, W
    Delaney, C
    Jemal, M
    Norton, J
    Uderman, H
    Ford, N
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI86 - PI86
12345